Application of beta, beta-dimethylacryloyl alkannin in preparation of polymyxin E synergist
Through the combination of β,β-dimethacryl akanin and polymyxin E, the problem of polymyxin E resistant bacteria was solved, significantly reducing the minimum inhibitory concentration of drug-resistant bacteria and increasing sensitivity The antibacterial activity of bacteria provides a new drug combination that restores bacterial sensitivity and has important clinical application value.
Patent Information
- Application Number
- CN202411235342.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-09-04
AI Technical Summary
The clinical application of polymyxin E is threatened by bacterial resistance, especially polymyxin E-resistant bacteria caused by plasmid-mediated mcr-1 resistance gene and chromosome-mediated two-component system mutations, which increases Patient mortality and treatment difficulty.
Using a composition of β,β-dimethacryl akanin and polymyxin E, the broth micro-dilution chessboard method and time-bactericidal curve experiment was used to determine its inhibition of polymyxin E resistance bacteria and Synergistic effects in sensitive bacteria reduce the amount of polymyxin E used and restore the bacteria's sensitivity to polymyxin E.
It significantly reduces the minimum inhibitory concentration of polymyxin E against polymyxin E-resistant bacteria, improves the antibacterial activity of polymyxin E-sensitive bacteria, and provides a new drug combination to restore bacterial sensitivity. It has important clinical application value.
Smart Images

Figure CN118924727A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedicine, and in particular to application of β,β-dimethylacryloyl acannin in the preparation of a polymyxin E synergist. Background Art
[0002] Polymyxin E is a polypeptide antibiotic produced by Bacillus polymyxa, which has an inhibitory effect on most Gram-negative bacteria. The mechanism by which polymyxin E exerts its antibacterial effect is that it can interact with the lipid A part of the bacterial outer membrane LPS, resulting in changes in bacterial membrane permeability and the outflow of contents, thereby inhibiting bacterial growth and causing bacterial death. In recent years, with the increasingly severe forms of bacterial resistance, polymyxin E has become one of the important drugs for the clinical treatment of multidrug-resistant bacterial infections. At the same time, the increasing resistance rate of multidrug-resistant pathogens to polymyxin E has increased the mortality rate of patients with sepsis, which has further increased the burden of polymyxin E in clinical application.
[0003] Studies have shown that mutations in the chromosome-mediated two-component systems PhoPQ and PmrAB can regulate eptA or arnT expression and insert pEtN or L-Ara4N into lipid A, thereby reducing the affinity of polymyxins for LPS. In addition, the emergence of the plasmid-mediated polymyxin resistance gene mcr-1 in 2015 and the widespread prevalence of the mcr family seriously threatened the clinical application of polymyxin E. Therefore, it is urgent to find a synergist that can increase the sensitivity of bacteria to polymyxin E in order to restore the sensitivity of bacteria to polymyxin E.
[0004] β,β-dimethylacryloyl akanin is a hydroxynaphthoquinone compound and one of the active ingredients of the traditional Chinese herbal medicine Lithospermum officinale, which is commonly used in clinical practice. It has multiple pharmacological effects such as antibacterial, anti-inflammatory, antioxidant, anti-tumor, immunomodulatory, and wound healing. Studies have shown that β,β-dimethylacryloyl akanin inhibits the proliferation of colorectal cancer cells and skin cancer cells by directly targeting fibroblast growth factor receptor 1 (FGFR1) and inhibiting its activity. In addition, β,β-dimethylacryloyl akanin can also act as an antagonist of TLR7 / 8, providing ideas for the treatment of autoimmune diseases with similar pathogenesis to psoriasis. However, to date, there has been no report on the combined use of β,β-dimethylacryloyl akanin and polymyxin E to inhibit polymyxin E-resistant bacteria. Summary of the invention
[0005] The object of the present invention is to provide application of β,β-dimethylacryloyl akanin in preparing a polymyxin E synergist.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides application of β,β-dimethylacryloyl akanin in preparing a polymyxin E synergist.
[0008] The present invention also provides an antibacterial composition, comprising β,β-dimethylacryloyl akanin and polymyxin E.
[0009] Preferably, the mass ratio of β,β-dimethylacryloyl akanin to polymyxin E is 0.5-512:1.
[0010] Preferably, the final concentration of the β,β-dimethylacryloyl akanin in the composition is 1 to 8 μg / mL;
[0011] Preferably, the final concentration of the polymyxin E in the composition is 0.0078-2 μg / mL.
[0012] The present invention also provides the use of the antibacterial composition in inhibiting polymyxin E-resistant bacteria or polymyxin E-sensitive bacteria.
[0013] Preferably, the polymyxin E-resistant bacteria are plasmid-mediated mcr-positive bacteria or resistant bacteria caused by mutations in the binary regulatory system; the polymyxin E-sensitive bacteria are Gram-negative bacteria that are sensitive to polymyxin E.
[0014] Preferably, the drug-resistant bacteria caused by the mcr-positive bacteria and / or binary regulatory system mutations are: mcr-1-positive Klebsiella pneumoniae 20, mcr-8-positive Klebsiella pneumoniae 126, mcr-9-positive Klebsiella pneumoniae 57, mgrB-mutated Klebsiella pneumoniae 251, mcr-1-positive Escherichia coli ZJ71, mcr-3-positive Escherichia coli pHSG299-mcr-3, binary regulatory system-mutated Escherichia coli BW25113-pmrBWT or mcr-9-positive Salmonella 5;
[0015] Preferably, the Gram-negative bacteria that are sensitive to polymyxin E are Klebsiella pneumoniae, Escherichia coli, Salmonella, Acinetobacter baumannii or Pseudomonas aeruginosa.
[0016] Preferably, when the antibacterial composition acts on Klebsiella pneumoniae, the mass ratio of β,β-dimethylacryloyl akanin to polymyxin E is 0.5-16:1; at this time, the final concentration of β,β-dimethylacryloyl akanin in the antibacterial composition is 1-4 μg / mL, and the final concentration of polymyxin E is 0.125-2 μg / mL;
[0017] Preferably, when the antibacterial composition acts on Escherichia coli, the mass ratio of β,β-dimethylacryloyl akanin to polymyxin E is 8 to 64:1; at this time, the final concentration of β,β-dimethylacryloyl akanin in the antibacterial composition is 4 to 8 μg / mL, and the final concentration of polymyxin E is 0.125 to 0.5 μg / mL;
[0018] Preferably, when the antibacterial composition acts on Salmonella resistant to polymyxin E, the mass ratio of β,β-dimethylacryloyl akanin to polymyxin E is 12 to 20:1; at this time, the final concentration of β,β-dimethylacryloyl akanin in the antibacterial composition is 6 to 10 μg / mL, and the final concentration of polymyxin E is 0.4 to 0.6 μg / mL;
[0019] Preferably, when the antibacterial composition acts on polymyxin E-sensitive bacteria, the mass ratio of β,β-dimethylacryloyl akanin to polymyxin E is 16-512:1; at this time, the final concentration of β,β-dimethylacryloyl akanin in the antibacterial composition is 2-4 μg / mL, and the final concentration of polymyxin E is 0.0078-0.125 μg / mL (except Salmonella and Pseudomonas aeruginosa).
[0020] The present invention also provides a drug for resisting bacterial infection, comprising the antibacterial composition.
[0021] Preferably, the dosage form of the antibacterial infection drug is tablets, creams, capsules, sustained-release tablets, controlled-release tablets, oral liquids, syrups, dropping pills, injection liquid dosage forms or freeze-dried powder injection dosage forms.
[0022] Compared with the prior art, the present invention has the following beneficial effects:
[0023] The present invention uses a broth microdilution chessboard method and a time-kill curve experiment to find that β,β-dimethylacryloyl akanin can cooperate with polymyxin E to inhibit plasmid-mediated mcr-positive bacteria and drug-resistant bacteria caused by binary regulatory system mutations (such as mcr-1-positive Klebsiella pneumoniae 20, mcr-8-positive Klebsiella pneumoniae 126, mcr-9-positive Klebsiella pneumoniae 57, mgrB mutant Klebsiella pneumoniae 251, mcr-1-positive Escherichia coli ZJ71, mcr-3-positive Escherichia coli pHSG299-mcr-3, binary regulatory system mutant Escherichia coli BW25113-pmrBWT, and mcr-9-positive Salmonella 5), thereby reducing the usage of polymyxin E and restoring the sensitivity of drug-resistant bacteria to polymyxin E. In addition, β,β-dimethylacryloyl acannin can also enhance the antibacterial activity of polymyxin E against polymyxin-sensitive bacteria (such as Klebsiella pneumoniae ATCC 13883, Escherichia coli ATCC 25922, and Acinetobacter baumannii ATCC 19606).
[0024] The present invention discovers for the first time that β,β-dimethylacryloyl akanin can restore the sensitivity of polymyxin E to polymyxin E-resistant bacteria, improve the antibacterial activity of polymyxin E against polymyxin E-resistant bacteria, and simultaneously improve the antibacterial activity of polymyxin E against polymyxin-sensitive bacteria, and has important application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.
[0026] Figure 1 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and colistin E against colistin E-resistant Klebsiella pneumoniae 20 detected by broth microdilution checkerboard method;
[0027] Figure 2 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and colistin E against colistin E-resistant Klebsiella pneumoniae 126 detected by broth microdilution checkerboard method;
[0028] Figure 3 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and colistin E against colistin E-resistant Klebsiella pneumoniae 57 detected by broth microdilution checkerboard method;
[0029] Figure 4 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and colistin E against colistin E-resistant Klebsiella pneumoniae 251 detected by broth microdilution checkerboard method;
[0030] Figure 5 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and polymyxin E against polymyxin E-resistant Escherichia coli ZJ71 detected by broth microdilution checkerboard method;
[0031] Figure 6 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and polymyxin E against polymyxin E-resistant Escherichia coli pHSG299-mcr-3 detected by broth microdilution checkerboard method;
[0032] Figure 7 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and polymyxin E against polymyxin E-resistant Escherichia coli BW25113-pmrBWT detected by broth microdilution checkerboard method;
[0033] Figure 8 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and colistin E against colistin E-resistant Salmonella 5 by broth microdilution checkerboard method;
[0034] Fig. 9 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and colistin E against colistin E-susceptible Klebsiella pneumoniae ATCC 13883 detected by broth microdilution checkerboard method;
[0035] Fig.10 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and colistin E against colistin E-susceptible Escherichia coli ATCC 25922 detected by broth microdilution checkerboard method;
[0036] Fig.11 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and colistin E against colistin E-susceptible Salmonella ATCC 13076 detected by broth microdilution checkerboard method;
[0037] Fig.12 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and colistin E against colistin E-susceptible Acinetobacter baumannii ATCC 19606 detected by broth microdilution checkerboard method;
[0038] Fig.13 is a heat map of the minimum inhibitory concentrations of β,β-dimethylacryloyl acannin and polymyxin E against polymyxin E-sensitive Pseudomonas aeruginosa PAO1 detected by broth microdilution checkerboard method;
[0039] Fig.14 Time-kill curves of different treatment groups against polymyxin E-resistant Klebsiella pneumoniae 126. DETAILED DESCRIPTION
[0040] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0041] Materials and reagents used in the present invention:
[0042] Polymyxin E is a product of Shanghai Aladdin Biochemical Technology Co., Ltd., with a potency of ≥19,000U / mg.
[0043] β,β-Dimethylacryloyl akanin is a product of Shanghai Taoshu Biological Company, with an effective content of 98%.
[0044] Polymyxin E-resistant bacteria (mcr-1-positive Klebsiella pneumoniae 20, mcr-8-positive Klebsiella pneumoniae 126, mcr-9-positive Klebsiella pneumoniae 57, mgrB mutant Klebsiella pneumoniae 251, mcr-1-positive Escherichia coli ZJ71, mcr-3-positive Escherichia coli pHSG299-mcr-3, binary regulatory system mutant Escherichia coli BW25113-pmrBWT, mcr-9-positive Salmonella 5) and polymyxin E-sensitive bacteria (Klebsiella pneumoniae ATCC 13883, Escherichia coli ATCC 25922, Salmonella ATCC13076, Acinetobacter baumannii ATCC 19606, Pseudomonas aeruginosa PAO1) were provided by the National Center for Veterinary Drug Safety Evaluation (Beijing).
[0045] MH II (cation-adjusted) liquid medium: Take 11 g of MH II (cation-adjusted) liquid medium powder (BD Company) and dissolve it in 500 mL of distilled water. Sterilize it with high-pressure steam at 121°C for 20 min and cool it for later use.
[0046] MH solid culture medium: 19 g MH agar culture medium powder (Beijing Luqiao Technology Co., Ltd.) was added to 500 mL distilled water, sterilized by high pressure steam at 121°C for 20 min, and cooled for later use.
[0047] Example 1
[0048] According to CLSI standards, the minimum inhibitory concentration (MIC) of β,β-dimethylacryloyl acannin and polymyxin E against polymyxin E-resistant and sensitive bacteria was determined by broth microdilution method. The specific steps are as follows:
[0049] 1. The bacterial suspension of polymyxin E-resistant and sensitive bacteria in the logarithmic growth phase was adjusted to 0.5 McFarland turbidity using a McFarland turbidimeter, and then diluted 100 times with MH II (cation-adjusted) broth medium to obtain a concentration of about 1×10 6 Dilutions of polymyxin E-resistant and sensitive bacteria with CFU / mL. Specific bacterial species are shown in Table 1.
[0050] 2. Weigh an appropriate amount of polymyxin E powder and dissolve it in deionized water to obtain a polymyxin E solution with a concentration of 5120 μg / mL, and then filter it with a sterile filter membrane (pore size of 0.22 μm) to obtain a polymyxin E stock solution.
[0051] Weigh an appropriate amount of β,β-dimethylacryloyl akanin powder, dissolve it in dimethyl sulfoxide (DMSO) to obtain a β,β-dimethylacryloyl akanin solution with a concentration of 5120 μg / mL, and then filter it with a sterile filter membrane (pore size of 0.22 μm) to obtain a β,β-dimethylacryloyl akanin stock solution.
[0052] 3. Take two 96-well microplates, add polymyxin E stock solution and β,β-dimethylacryloyl akanin stock solution to the first well, dilute them 2-fold with MH II (cation-regulated) broth medium, and inoculate 100 μL of polymyxin E resistant bacteria dilution solution in each well, so that the concentration range of β,β-dimethylacryloyl akanin and polymyxin E is 0-128 μg / mL. Among them, the positive control is the diluted bacterial solution (without drug), and the blank control is MH II (cation-regulated) broth.
[0053] 4. Incubate the 96-well microplate after step 3 at 37°C for 16 to 18 hours.
[0054] Experimental results: As shown in Table 1, the MIC of β,β-dimethylacryloyl akanin against polymyxin E-resistant bacteria was >128 μg / mL, and the MIC of polymyxin E against polymyxin E-resistant bacteria was ≥2 μg / mL, indicating that these strains were resistant to polymyxin E. The MIC of β,β-dimethylacryloyl akanin against polymyxin E-sensitive bacteria was >128 μg / mL, and the MIC of polymyxin E against polymyxin E-sensitive bacteria was 0.125-1 μg / mL.
[0055] Table 1 MICs (μg / mL) of β,β-dimethylacryloyl-arcanin and polymyxin E
[0056]
[0057]
[0058] Example 2
[0059] The broth microdilution chessboard method was used to detect the combined inhibitory index (Fractional Inhibitory Concentration Index, FICI) of β,β-dimethylacryloyl akanin and polymyxin E against polymyxin E-resistant bacteria and sensitive bacteria in Example 1. The specific steps are as follows:
[0060] 1. The bacterial suspension of polymyxin E-resistant and sensitive bacteria in the logarithmic growth phase was adjusted to 0.5 McFarland turbidity using a McFarland turbidimeter, and then diluted 100 times with MH II (cation-adjusted) broth medium to obtain a concentration of about 1×10 6 Dilutions of polymyxin E-resistant and sensitive bacteria in CFU / mL.
[0061] 2. Weigh an appropriate amount of polymyxin E powder, dissolve it in deionized water to obtain a polymyxin E solution with a concentration of 5120 μg / mL, and then filter it with a sterile filter membrane (pore size of 0.22 μm) to obtain a polymyxin E stock solution. Weigh an appropriate amount of β,β-dimethylacryloyl akanin powder, dissolve it in dimethyl sulfoxide (DMSO) to obtain a β,β-dimethylacryloyl akanin solution with a concentration of 5120 μg / mL, and then filter it with a sterile filter membrane (pore size of 0.22 μm) to obtain a β,β-dimethylacryloyl akanin stock solution.
[0062] 3. Take a 96-well microplate and inoculate each well with 100 μL of drug solution (mixed by diluting β,β-dimethylacryloyl akanin and polymyxin E in proportion) and 100 μL of polymyxin E-resistant bacteria and sensitive bacteria dilutions.
[0063] For the polymyxin E-resistant bacteria Klebsiella pneumoniae 20, the concentration of β,β-dimethylacryloyl akanin in each well in each row from top to bottom is 0, 0.25, 0.5, 1, 2, 4, 8, and 16 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 1, 2, 4, 8, 16, 32, and 64 μg / mL, respectively.
[0064] For the polymyxin E-resistant bacteria Klebsiella pneumoniae 126, the concentration of β,β-dimethylacryloyl akanin in each well in each row from top to bottom is 0, 0.5, 1, 2, 4, 8, 16, and 32 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 2, 4, 8, 16, 32, 64, and 128 μg / mL, respectively.
[0065] For the polymyxin E-resistant bacteria Klebsiella pneumoniae 57, the concentration of β,β-dimethylacryloyl akanin in each well in each row from top to bottom is 0, 0.25, 0.5, 1, 2, 4, 8, and 16 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 0.0313, 0.0625, 0.125, 0.25, 0.5, 1, and 2 μg / mL, respectively.
[0066] For the polymyxin E-resistant bacteria Klebsiella pneumoniae 251, the concentration of β,β-dimethylacryloyl akanin in each well in each row from top to bottom is 0, 0.5, 1, 2, 4, 8, 16, and 32 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 2, 4, 8, 16, 32, 64, and 128 μg / mL, respectively.
[0067] For the polymyxin E-resistant bacteria Escherichia coli ZJ71, the concentration of β,β-dimethylacryloyl akanin in each well in each row from top to bottom is 0, 0.5, 1, 2, 4, 8, 16, and 32 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 0.125, 0.25, 0.5, 1, 2, 4, and 8 μg / mL, respectively.
[0068] For the polymyxin E-resistant Escherichia coli pHSG299-mcr-3, the concentration of β,β-dimethylacryloylacarynine in each well in each row from top to bottom is 0, 0.5, 1, 2, 4, 8, 16, and 32 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 0.0313, 0.0625, 0.125, 0.25, 0.5, 1, and 2 μg / mL, respectively.
[0069] For the polymyxin E-resistant Escherichia coli BW25113-pmrBWT, the concentration of β,β-dimethylacryloylacarynine in each well in each row from top to bottom is 0, 0.5, 1, 2, 4, 8, 16, and 32 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 0.25, 0.5, 1, 2, 4, 8, and 16 μg / mL, respectively.
[0070] For the polymyxin E-resistant bacteria Salmonella 5, the concentration of β,β-dimethylacryloyl-acannin in each well in each row from top to bottom is 0, 0.5, 1, 2, 4, 8, 16, and 32 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 0.25, 0.5, 1, 2, 4, 8, and 16 μg / mL, respectively.
[0071] For the polymyxin E-sensitive bacteria Klebsiella pneumoniae ATCC 13883, the concentration of β,β-dimethylacryloyl akanin in each well in each row from top to bottom is 0, 0.25, 0.5, 1, 2, 4, 8, and 16 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 0.0078, 0.0156, 0.0313, 0.0625, 0.125, 0.25, and 0.5 μg / mL, respectively.
[0072] For the polymyxin E-sensitive bacteria Escherichia coli ATCC 25922, the concentration of β,β-dimethylacryloylarachnine in each well in each row from top to bottom is 0, 0.25, 0.5, 1, 2, 4, 8, and 16 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 0.0039, 0.0078, 0.0156, 0.0313, 0.0625, 0.125, and 0.25 μg / mL, respectively.
[0073] For the polymyxin E-sensitive bacteria Salmonella ATCC 13076, the concentration of β,β-dimethylacryloyl-arcanin in each well in each row from top to bottom is 0, 0.25, 0.5, 1, 2, 4, 8, and 16 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 0.0078, 0.0156, 0.0313, 0.0625, 0.125, 0.25, and 0.5 μg / mL, respectively.
[0074] For the polymyxin E-sensitive bacteria Acinetobacter baumannii ATCC 19606, the concentration of β,β-dimethylacryloylacannin in each well in each row from top to bottom is 0, 0.25, 0.5, 1, 2, 4, 8, and 16 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 0.0078, 0.0156, 0.0313, 0.0625, 0.125, 0.25, and 0.5 μg / mL, respectively.
[0075] For the polymyxin E-sensitive bacteria Pseudomonas aeruginosa PAO1, the concentration of β,β-dimethylacryloyl akanin in each well in each row from top to bottom is 0, 0.25, 0.5, 1, 2, 4, 8, and 16 μg / mL, respectively; the concentration of polymyxin E in each well in each column from left to right is 0, 0.0156, 0.0313, 0.0625, 0.125, 0.25, 0.5, and 1 μg / mL, respectively.
[0076] 4. After completing step 3, take the 96-well microplate and incubate at 37°C for 16 to 18 hours.
[0077] 5. After completing step 4, calculate the combined inhibitory index (FICI) value based on the minimum inhibitory concentration (MIC) of each drug to determine whether β,β-dimethylacryloyl acannin and polymyxin E have a synergistic effect.
[0078] FICI=(MIC 多黏菌素E联合 / MIC 多黏菌素E单用 )+(MIC β,β-二甲基丙烯酰阿卡宁联合 / MIC β,β-二甲基丙烯酰阿卡宁单用 )
[0079] The judgment standard is: when FICI≤0.5, it is judged that the two have a synergistic effect.
[0080] Test results: Figures 1 to 13 The optimal drug combination calculated by the FICI method is marked with a triangle. The experiment was repeated three times and the results were averaged. The statistical results are shown in Table 2.
[0081] Table 2 Combined antibacterial effect of β,β-dimethylacryloyl acannin combined with polymyxin E against polymyxin E-resistant and sensitive bacteria
[0082]
[0083]
[0084] The results showed that β,β-dimethylacryloyl akanin combined with polymyxin E could significantly reduce the MIC values of polymyxin E against polymyxin E-resistant Klebsiella pneumoniae, Escherichia coli and Salmonella, as well as the MIC values of polymyxin E-sensitive Klebsiella pneumoniae, Escherichia coli and Acinetobacter baumannii, but had no synergistic effect against polymyxin E-sensitive Salmonella and Pseudomonas aeruginosa.
[0085] For polymyxin E-resistant Klebsiella pneumoniae, the mass ratio of β,β-dimethylacryloyl-acampine to polymyxin E is 0.5-16:1; at this time, the minimum inhibitory concentration of β,β-dimethylacryloyl-acampine is 1-4μg / mL, and the minimum inhibitory concentration of polymyxin E is 0.125-2μg / mL.
[0086] For polymyxin E-resistant Escherichia coli, the mass ratio of β,β-dimethylacryloyl-acampine to polymyxin E is 8-64:1; at this time, the minimum inhibitory concentration of β,β-dimethylacryloyl-acampine is 4-8μg / mL, and the minimum inhibitory concentration of polymyxin E is 0.125-0.5μg / mL.
[0087] For Salmonella resistant to polymyxin E, the mass ratio of β,β-dimethylacryloyl-acampine to polymyxin E was 16:1; at this time, the minimum inhibitory concentration of β,β-dimethylacryloyl-acampine was 8μg / mL, and the minimum inhibitory concentration of polymyxin E was 0.5μg / mL.
[0088] For bacteria sensitive to polymyxin E, the mass ratio of β,β-dimethylacryloyl-acampine to polymyxin E is 16-512:1; at this time, the minimum inhibitory concentrations of β,β-dimethylacryloyl-acampine are 2-4 μg / mL, and the minimum inhibitory concentration of polymyxin E is 0.0078-0.125 μg / mL (except Salmonella and Pseudomonas aeruginosa).
[0089] The above results indicate that β,β-dimethylacryloyl acanin can synergize with polymyxin E to exert antibacterial effects, thereby treating infections caused by polymyxin E-resistant bacteria and at the same time increasing the sensitivity of polymyxin E-sensitive bacteria to polymyxin E.
[0090] Example 3
[0091] Time-kill curve of β,β-dimethylacryloyl acannin combined with polymyxin E against polymyxin E-resistant Klebsiella pneumoniae 126:
[0092] 1. The polymyxin E-resistant Klebsiella pneumoniae 126 culture in the logarithmic growth phase was adjusted to a McFarland turbidity of 0.5 using a McFarland turbidimeter, and then diluted 100 times with MH broth medium to obtain a concentration of about 1×10 6 Dilution of polymyxin E-resistant bacteria with CFU / mL.
[0093] 2. Take 12 test tubes and randomly divide them into a blank group, a β,β-dimethylacryloyl akanin group, a polymyxin E group, and a combined group, with 3 test tubes in each group, and perform the following treatments:
[0094] Blank group (Control): No drug was added to the test tube.
[0095] β,β-dimethylacryloyl akanin group: according to the MIC value of β,β-dimethylacryloyl akanin against Klebsiella pneumoniae 126 in the broth microdilution checkerboard method experiment, 5120 μg / mL of β,β-dimethylacryloyl akanin stock solution was added to make the final concentration of β,β-dimethylacryloyl akanin in the system 1 / 8 × MIC value of β,β-dimethylacryloyl akanin against Klebsiella pneumoniae 126 (16 μg / mL);
[0096] Polymyxin E group: According to the MIC value of polymyxin E against Klebsiella pneumoniae 126 in the broth microdilution chessboard method experiment, 5120 μg / mL of polymyxin E stock solution was added to make the final concentration of polymyxin E in the system 1 / 32×MIC value of polymyxin E against Klebsiella pneumoniae 126 (16 μg / mL);
[0097] Combination group: β,β-dimethylacryloyl akanin and polymyxin E were added to the system to make the final concentrations of β,β-dimethylacryloyl akanin and polymyxin E to Klebsiella pneumoniae 126 1 / 8×MIC and 1 / 32×MIC values, respectively.
[0098] 3. Add an equal volume (1 mL) of the resistant bacteria dilution to each test tube. Then place the 12 test tubes in a 37°C shaker and culture at 200 rpm. This is 0 h. During the culture period, take 100 μL of the culture solution at 0, 2, 4, 8, 12 and 24 h for 10-fold gradient dilution, spread on MH solid culture medium, culture at 37°C for 24 h, and count the colonies.
[0099] 4. After completing step 3, draw a time-sterilization curve with the culture time as the horizontal axis and the log10 value of the colony count as the vertical axis.
[0100] Time-kill curve of polymyxin E-resistant Klebsiella pneumoniae 126 is shown in Fig.14 (CFU is colony forming unit).
[0101] The results show that ( Fig.14 ), compared with the blank group, β,β-dimethylacryloyl akanin group and polymyxin E group, the combined group could completely inhibit bacterial growth at 2 h, and the colony forming unit could be reduced by about 9 log10 values at 24 h, which significantly enhanced the antibacterial activity of polymyxin E against polymyxin E-resistant bacteria, showing a synergistic bactericidal effect.
[0102] It can be seen from the above examples that β,β-dimethylacryloyl akanin combined with polymyxin E can enhance the antibacterial activity of polymyxin E against polymyxin E-resistant Klebsiella pneumoniae 126, that is, β,β-dimethylacryloyl akanin combined with polymyxin E can inhibit polymyxin E-resistant Klebsiella pneumoniae 126.
[0103] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Application of β,β-dimethylacryloyl akanin in the preparation of polymyxin E enhancer.
2. An antibacterial composition, It is characterized in that These include β,β-dimethylacryloyl-arcanin and polymyxin E.
3. The composition according to claim 2, It is characterized in that The mass ratio of the β,β-dimethylacryloyl akanin to polymyxin E is 0.5-512:
1.
4. The composition according to claim 3, It is characterized in that The final concentration of the β,β-dimethylacryloyl akanin in the composition is 1 to 8 μg / mL; the final concentration of the polymyxin E in the composition is 0.0078 to 2 μg / mL.
5. Use of the antibacterial composition according to any one of claims 2 to 4 in inhibiting polymyxin E-resistant bacteria or polymyxin E-sensitive bacteria.
6. The use according to claim 5, It is characterized in that The polymyxin E-resistant bacteria are plasmid-mediated mcr-positive bacteria or resistant bacteria caused by mutations in the binary regulatory system; the polymyxin E-sensitive bacteria are Gram-negative bacteria that are sensitive to polymyxin E.
7. The use according to claim 6, It is characterized in that The drug-resistant bacteria caused by the mcr-positive bacteria and / or binary regulatory system mutations are: mcr-1 positive Klebsiella pneumoniae 20, mcr-8 positive Klebsiella pneumoniae 126, mcr-9 positive Klebsiella pneumoniae 57, mgrB mutant Klebsiella pneumoniae 251, mcr-1 positive Escherichia coli ZJ71, mcr-3 positive Escherichia coli pHSG299-mcr-3, binary regulatory system mutant Escherichia coli BW25113-pmrBWT or mcr-9 positive Salmonella 5; The Gram-negative bacteria that are sensitive to polymyxin E are Klebsiella pneumoniae, Escherichia coli, Salmonella, Acinetobacter baumannii or Pseudomonas aeruginosa.
8. The use according to claim 6 or 7, It is characterized in that When the antibacterial composition acts on Klebsiella pneumoniae, the mass ratio of β,β-dimethylacryloyl akanin to polymyxin E is 0.5-16:1; at this time, the final concentration of β,β-dimethylacryloyl akanin in the antibacterial composition is 1-4 μg / mL, and the final concentration of polymyxin E is 0.125-2 μg / mL; When the antibacterial composition acts on Escherichia coli, the mass ratio of β,β-dimethylacryloyl akanin to polymyxin E is 8-64:1; at this time, the final concentration of β,β-dimethylacryloyl akanin in the antibacterial composition is 4-8 μg / mL, and the final concentration of polymyxin E is 0.125-0.5 μg / mL; When the antibacterial composition acts on Salmonella resistant to polymyxin E, the mass ratio of β,β-dimethylacryloyl akanin to polymyxin E is 12-20:1; at this time, the final concentration of β,β-dimethylacryloyl akanin in the antibacterial composition is 6-10 μg / mL, and the final concentration of polymyxin E is 0.4-0.6 μg / mL; When the antibacterial composition acts on polymyxin E-sensitive bacteria, the mass ratio of β,β-dimethylacryloyl akanin to polymyxin E is 16-512:1; at this time, the final concentration of β,β-dimethylacryloyl akanin in the antibacterial composition is 2-4 μg / mL, and the final concentration of polymyxin E is 0.0078-0.125 μg / mL.
9. A drug for fighting bacterial infection, It is characterized in that The invention comprises the antibacterial composition according to any one of claims 2 to 4.
10. The drug for antibacterial infection according to claim 9, Features: The dosage form of the antibacterial infection drug is tablets, creams, capsules, sustained-release tablets, controlled-release tablets, oral liquids, syrups, dripping pills, injection liquid dosage forms or freeze-dried powder injection dosage forms.
Citation Information
Patent Citations
Medicine containing alkannin compound as active component
CN101288665A
Beta,beta-dimethyl-acry-lalkannin and application in preparing medicines for inhibiting drug-resistant bacteria
CN101597230A
Lithospermum naphthoquinone derivative and application of lithospermum naphthoquinone derivative combined with antibiotics in preparation of medicines for treating bacterial infection diseases
CN115969824A
Application of acetylshikonin as conjugational transfer inhibitor in product or medicine for controlling and preventing transmission of drug-resistant gene positive plasmid in environment and body
CN118512437A
